Status | Study |
Recruiting |
Study Name: Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions Condition: Pheochromocytoma Paraganglioma Inherited Cancer Syndrome Date: 2017-05-05 Interventions: Genetic: Genetic screening Germline and/or tumor samples will be screened for mutations |
Recruiting |
Study Name: Familial Investigations of Childhood Cancer Predisposition Condition: Acute Leukemia Adenomatous Polyposis Adrenocortical Carcin Date: 2017-02-08 |
Not yet recruiting |
Study Name: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Condition: Malignant Adrenal Gland Pheochromocytoma Malignant Paraganglioma Date: 2016-12-28 Interventions: Other: Laboratory Biomarker Analysis |
Available |
Study Name: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2016-11-08 Interventions: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who |
Recruiting |
Study Name: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Condition: Neuroendocrine Tumors Carcinoma, Small Cell Lung Carcinoma Date: 2016-10-13 Interventions: Drug: PEN-221 Administration of PEN-221 once every three weeks |
Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition: Acinar Cell Carcinoma Adrenal Cortex Carcinoma Adrenal Gla Date: 2016-07-13 Interventions: Procedure: Biospecimen Collection |
Available |
Study Name: 18F-FDOPA PET in Neuroendocrine Tumours Condition: Thyroid Cancer, Medullary Carcinoid Tumor Pheochromocytoma Date: 2015-04-27 Interventions: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) |
Recruiting |
Study Name: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies Condition: Neuroendocrine Tumor Paraganglioma Carcinoid Tumors Date: 2014-06-25 Interventions: Drug: DOTA-TOC PET/CT Single Gallium-68 DOTA-TOC PET/CT in patients with somatostatin receptor positive |
Active, not recruiting |
Study Name: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Condition: Paragangliomas Pheochromocytomas Date: 2014-06-04 Interventions: Other: PET-CT |
Active, not recruiting |
Study Name: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2013-10-19 Interventions: Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |